Skip to content
StackItSmart
BHuman cohort / observational

Citrus Bergamot

Bergamot

Citrus bergamot (Citrus bergamia) is a Mediterranean citrus whose fruit/juice-derived polyphenolic fraction (BPF) - rich in flavonoids including naringin, neohesperidin, brutieridin and melitidin - is sold as an oral "organ-support"/cardiometabolic supplement, primarily marketed to lower cholesterol and triglycerides and support the liver. Multiple small randomized controlled trials and a meta-analysis of 14 RCTs report reductions in total cholesterol, LDL-C and triglycerides with modest HDL-C increases (10.1002/ptr.7647). The human evidence base is dominated by small, short (4-12 week), largely single-research-group and industry-associated trials with high heterogeneity and low methodological quality, and dedicated safety/toxicology studies in humans are essentially absent - so most organ-system risks are simply uncharacterized rather than proven safe. This is a lipid-active substance: it is not a substitute for prescribed statin/lipid therapy, it can theoretically compound effects or interactions when combined with lipid drugs, and its citrus flavonoids raise a plausible (though not clinically quantified) concern for CYP/drug-interaction and, for the essential-oil form, phototoxicity. Anyone using it for a cardiovascular indication should do so under a clinician with baseline and follow-up bloodwork, not as self-directed therapy.

Clinical readoutAncillary · organ-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
Not reliably esta…
Route
Oral
Evidence
B
Active
Dosed once or twice dai…
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Not reliably established in humans. Bergamot flavonoid glycosides (e.g., naringin) are poorly absorbed intact, undergo gut-microbial deglycosylation to aglycones (naringenin) and extensive phase-II conjugation; no validated elimination half-life for a standardized BPF is available in the retrieved primary literature.
Pharmacology

Mechanism of action

Bergamot's activity is attributed to its flavonoid/polyphenol content. Proposed mechanisms from preclinical and mechanistic human-adjacent work: (1) inhibition of HMG-CoA reductase, the rate-limiting cholesterol-synthesis enzyme (statin-like), reported alongside reduced urinary mevalonate in patients (10.1016/j.fitote.2010.10.014; 10.1016/j.ijcard.2013.08.125); (2) activation of AMP-activated protein kinase (AMPK), downregulating lipogenic genes SREBF1c/2, HMGCR, FASN, ACACA and SCD1 in HepG2 hepatocytes, reducing intracellular cholesterol and triglyceride (10.1002/ptr.7897); (3) stimulation of hepatic lipophagy/autophagy of lipid droplets and antioxidant effects (reduced LOX-1, malondialdehyde, oxidized-LDL) in preclinical NAFLD/NASH models (10.1016/j.jnutbio.2015.03.008; 10.1038/s41598-020-59485-3). Net reported effect is reduced cholesterol/triglyceride synthesis plus antioxidant/anti-inflammatory activity. Mechanistic detail rests heavily on in-vitro and animal data.
Kinetics

Pharmacokinetics

Half-life

Not reliably established in humans. Bergamot flavonoid glycosides (e.g., naringin) are poorly absorbed intact, undergo gut-microbial deglycosylation to aglycones (naringenin) and extensive phase-II conjugation; no validated elimination half-life for a standardized BPF is available in the retrieved primary literature.

Active duration

Dosed once or twice daily in trials over 4-12 weeks; lipid effects are a cumulative pharmacodynamic response over weeks rather than an acute per-dose effect. Duration data are for monitoring/washout planning, not otherwise.

Route

Oral (capsules/tablets of polyphenolic fraction, phytosome, or juice-derived extract).

Metabolism & clearance

Low oral bioavailability of parent flavonoids; a lecithin/phytosome formulation increased naringin absorption ~2.5-fold versus standard BPF in a human comparison (10.2174/1871530319666181203151513). Metabolism is via gut microbiota and hepatic conjugation; renal/biliary excretion of metabolites. Precise clearance parameters are not characterized in humans.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Reduced total cholesterol in mildly-to-moderately hypercholesterolemic adults (10.1002/ptr.7897; 10.1002/ptr.7647)
  • Reduced LDL-C, including small-dense atherogenic LDL particles (10.2174/1871530319666181203151513; 10.1016/j.ijcard.2013.08.125)
  • Reduced triglycerides (10.1002/ptr.7897; 10.1002/ptr.7647)
  • Modest increase in HDL-C in some trials/meta-analysis (10.1002/ptr.7647; 10.1016/j.fitote.2010.10.014)
  • Reduced fasting plasma glucose in hyperlipidemic/type-2-diabetic patients (10.1016/j.fitote.2010.10.014; 10.2174/1871530319666181203151513)
  • Reduced ApoB and non-HDL-C (10.1002/ptr.7897)
  • Reductions in liver transaminases (AST/GOT, ALT/GPT) and GGT reported in one 12-week RCT of a whole-fruit extract (10.1002/ptr.7897)
  • Reduced waist circumference and visceral adipose tissue when a bergamot phytosome was combined with artichoke extract (10.3390/nu14010108)
  • When added to rosuvastatin, enhanced LDL-lowering and reduced oxidative vascular-damage biomarkers versus statin alone (10.1016/j.ijcard.2013.08.125)
Safety

Adverse effects by system

Cardiovascular

No direct cardiotoxicity signal identified. Trials report favorable surrogate lipid/oxidative changes, but there are no cardiovascular outcome (event) data and no human safety study powered to detect harm; net cardiovascular effect on hard endpoints is unknown (10.1002/ptr.7647).

Hepatic

No hepatotoxicity signal in the retrieved human trials; one 12-week RCT reported reductions rather than elevations in AST/ALT/GGT (10.1002/ptr.7897), and preclinical NAFLD/NASH models show reduced hepatic steatosis and ALT (10.1016/j.jnutbio.2015.03.008; 10.1038/s41598-020-59485-3). However, dedicated hepatic-safety monitoring across trials is limited, so idiosyncratic risk cannot be excluded.

Endocrine / HPTA

No known effect on the hypothalamic-pituitary-gonadal axis; bergamot is not androgenic, estrogenic, or a SERM and no HPTA/testosterone data exist. Effects on glucose metabolism (lowering fasting glucose) are reported but are metabolic, not gonadal (10.2174/1871530319666181203151513).

Reproductive

No adequate human data. No fertility, pregnancy, or lactation safety studies were identified; use in pregnancy/breastfeeding cannot be considered established as safe.

Neuropsychiatric

No adequate human data for oral bergamot supplementation; no neuropsychiatric adverse effects have been systematically assessed or reported in the retrieved lipid trials.

Renal

No adequate human data. Trials measured renal function biomarkers as safety parameters in at least one protocol but no adverse renal signal or dedicated renal-safety analysis is available; renal effects are essentially uncharacterized (10.1186/s13063-020-04551-4).

Hematologic

No adequate human data on hematologic parameters; no bleeding, cytopenia, or coagulation signal has been characterized in the retrieved literature.

Dermatologic

Oral polyphenolic extracts: no dermatologic adverse signal reported. Separately, bergamot essential oil contains the furanocoumarin bergapten (5-methoxypsoralen), an established phototoxic/photosensitizing agent; defurocoumarinized (bergapten-removed) preparations minimize this phototoxicity risk. This concern applies to essential-oil/topical exposure, not necessarily to flavonoid oral fractions (10.1016/j.talanta.2025.127579).

Recovery

HPTA suppression & recovery

Suppression: None expected. Bergamot is a non-hormonal citrus flavonoid supplement with no known androgenic, estrogenic, or SERM activity and no evidence of HPTA suppression.

No HPTA suppression is anticipated and therefore no recovery protocol is implicated. This is not a SERM and has no role in post-cycle or endocrine-recovery contexts; any hormonal or fertility concerns should be directed to a qualified endocrinologist rather than managed with this supplement.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at baseline and after ~8-12 weeksLiver function tests (AST/ALT, GGT) at baseline and follow-upFasting plasma glucose / HbA1c, especially in diabetics or those on glucose-lowering drugsRenal function (creatinine/eGFR) as general safety baseline

Cadence: Baseline before starting, then reassess lipids and LFTs at roughly 8-12 weeks; ongoing monitoring per clinician if continued, and additional glucose monitoring for diabetics.

Warning signs — seek care
  • Symptoms of hypoglycemia (shakiness, sweating, confusion) if combined with antidiabetic drugs
  • New muscle pain/weakness if used alongside a statin (evaluate for myopathy)
  • Signs of liver injury: jaundice, dark urine, right-upper-quadrant pain, unusual fatigue
  • Allergic reaction (rash, swelling, difficulty breathing)
  • Skin burn/blistering after sun exposure when using bergamot essential oil topically
Do not use if

Contraindications

  • Do not use as a replacement for clinician-prescribed statin or other lipid-lowering therapy; lipid management should be physician-directed
  • Caution/clinician oversight when combined with statins or other lipid-lowering drugs, given additive lipid effects and shared HMG-CoA-reductase mechanism (10.1016/j.ijcard.2013.08.125)
  • Caution with concurrent glucose-lowering therapy in diabetics, given reported fasting-glucose reductions and hypoglycemia potential (10.2174/1871530319666181203151513)
  • Pregnancy and breastfeeding: no safety data - avoid
  • Known citrus allergy
  • Theoretical caution with narrow-therapeutic-index drugs metabolized by CYP3A4 given citrus-flavonoid/furanocoumarin content; interaction not quantified in the retrieved human literature
  • Bergamot essential oil (distinct from oral flavonoid extract) should not be applied to skin before sun/UV exposure due to bergapten phototoxicity (10.1016/j.talanta.2025.127579)
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Treat bergamot as an adjunct/experimental supplement, not a replacement for prescribed statin or other physician-directed lipid therapy; if you have diagnosed dyslipidemia or cardiovascular risk, manage it with a clinician.
  • Get baseline bloodwork (lipids, liver enzymes, fasting glucose) before starting and repeat at ~8-12 weeks so effects and any harms are tracked objectively.
  • If combining with a statin, do so only under clinician supervision and report any new muscle pain or weakness promptly.
  • If you take glucose-lowering medication, monitor for hypoglycemia because bergamot can lower fasting glucose.
  • Because citrus flavonoids/furanocoumarins can theoretically affect drug metabolism, review all prescription medications (especially narrow-therapeutic-index and CYP3A4 drugs) with a pharmacist or physician before use.
  • Avoid in pregnancy and breastfeeding - no safety data.
  • Stop and seek medical care for signs of liver injury (jaundice, dark urine, RUQ pain), allergic reaction, or hypoglycemia.
  • Do not apply bergamot essential oil to skin before sun/UV exposure due to phototoxic bergapten; this is separate from oral flavonoid extracts.
  • Recognize that most organ-system safety data are absent - 'no reported harm' here means understudied, not proven safe.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    Bergamot supplementation reduces total cholesterol, LDL-C and triglycerides and modestly raises HDL-C across RCTs (meta-analysis of 14 trials), but with high heterogeneity, inconsistent results and low study quality requiring higher-quality confirmation.

    Meta-analysisDOI 10.1002/ptr.7647 ↗

  2. 02

    A 12-week double-blind placebo-controlled RCT (400 mg whole-fruit extract, 50 moderately hypercholesterolemic adults) reduced total cholesterol, triglycerides, LDL-C, non-HDL-C, ApoB and fasting glucose, and lowered liver enzymes (AST/ALT/GGT); mechanism involves AMPK activation and downregulation of lipogenic genes in hepatocytes.

    RCTDOI 10.1002/ptr.7897 ↗

  3. 03

    Bergamot polyphenolic fraction reduces total and LDL cholesterol and triglycerides, raises HDL, lowers blood glucose, and inhibits HMG-CoA reductase; shown in rats and 237 hyperlipemic/hyperglycemic patients over 30 days.

    RCTDOI 10.1016/j.fitote.2010.10.014 ↗

  4. 04

    In a double-blind RCT in 60 type-2-diabetic patients with mixed hyperlipidemia, standard BPF and a phytosome BPF reduced fasting glucose, LDL-C and triglycerides, raised HDL-C, and reduced small-dense atherogenic LDL; the phytosome formulation increased naringin absorption ~2.5-fold.

    RCTDOI 10.2174/1871530319666181203151513 ↗

  5. 05

    Adding BPF (1000 mg/day) to rosuvastatin enhanced LDL-C lowering versus statin alone and reduced oxidative vascular-damage biomarkers (LOX-1, malondialdehyde, phospho-PKB) in 77 hyperlipidemic patients.

    RCTDOI 10.1016/j.ijcard.2013.08.125 ↗

  6. 06

    Bergamot phytosome (600 mg) combined with artichoke extract (100 mg) reduced total and LDL cholesterol, waist circumference and visceral adipose tissue in overweight adults with mild hypercholesterolemia over 60 days.

    RCTDOI 10.3390/nu14010108 ↗

  7. 07

    Bergamot polyphenol fraction reduces hepatic steatosis via stimulation of lipophagy/autophagy in a diet-induced rat model of metabolic syndrome/NAFLD (preclinical).

    PreclinicalDOI 10.1016/j.jnutbio.2015.03.008 ↗

  8. 08

    Bergamot polyphenol formulation (BPF99) reduced ALT, triglycerides and LDL-C and improved NASH resolution/histology in a diet-induced mouse model (preclinical).

    PreclinicalDOI 10.1038/s41598-020-59485-3 ↗

  9. 09

    Bergamot essential oil contains the furanocoumarin bergapten (5-methoxypsoralen), a phototoxic agent; defurocoumarinized preparations minimize phototoxicity risk while retaining antioxidant capacity.

    PreclinicalDOI 10.1016/j.talanta.2025.127579 ↗

  10. 10

    This published clinical-trial protocol (a planned, not-yet-conducted RCT of a bergamot/olive/vitamin-K2 supplement, ACTRN12619000170123) specifies monitoring of lipid, glycemic, renal, liver and cardiac/muscular safety biomarkers, reflecting standard safety surveillance rather than demonstrated organ toxicity.

    ReviewDOI 10.1186/s13063-020-04551-4 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice